Table 4 Pathological features and oncological outcomes
Overall (n = 137) | Propensity score-matched pairs (n = 88) | |||||
|---|---|---|---|---|---|---|
Lap (n = 85) | SILS (n = 52) | P value | Lap (n = 44) | SILS (n = 44) | P value | |
Tumor size, mm, median (IQR) | 25 (16-45) | 40 (26-50) | 0.038 | 25 (15-50) | 38 (23-45) | 0.128 |
Proximal margin, mm, median (IQR) | 105 (95-110) | 110 (105-118) | 0.749 | 105 (90-115) | 110 (95-110) | 0.648 |
Distal margin, mm, median (IQR) | 95 (80-110) | 90 (85-108) | 0.545 | 95 (88-110) | 90 (85-110) | 0.701 |
Number of harvested lymph nodes, median (IQR) | 14 (8-22) | 21 (12-29) | <0.001 | 14 (8-22) | 20 (11-27) | 0.043 |
Tumor invasion, n (%) | 0.353 | 0.568 | ||||
pT1 | 25 (29.4) | 10 | 14 (31.8) | 10 | ||
pT2 | 12 (14.1) | (19.2) | (22.7) | |||
pT3 | 34 (40) | 6 (13.6) | ||||
pT4 | 14 (16.5) | 5 (9.6) 28 (53.9) 9 (17.3) | 16 (36.4) 8 (18.2) | 4 (9.1) 22 (50) 8 (18.2) | ||
Lymph node metastasis, n (%) | 0.251 | 0.086 | ||||
pN0 | 62 (72.9) | 31 (59.6) | 33 (75) | 26 (59.1) | ||
pN1a | 11 (12.9) | 7 (13.5) | 6 (13.6) | 7 (15.9) | ||
pN1b | 6 (7.1) | 8 (15.4) | 1 (2.3) | 6 (13.6) | ||
pN2a | 5 (5.9) | 3 (5.8) | 4(9.1) | 2 (4.6) | ||
pN2b | 1 (1.2) | 3 (5.8) | 0 | 3 (6.8) | ||
Positive radial margin, n (%) | 0 | 0 | – | 0 | 0 | – |
pTNM stage, n (%) | 0.293 | 0.343 | ||||
I | 32 (37.7) | 14 (26.9) | 18 (40.9) | 13 | ||
II | 30 (35.3) | 18 (34.6) | 15 (34.1) | (29.6) | ||
III | 22 (25.9) | 20 (38.5) | 11 (25) | 14 (31.8) | ||
IV | 1 (1.2) | 0 | 10 (22.7) | 17 (38.6) | ||
Adjuvant chemotherapy (stage II or III), n (%) | 19 (36.5) | 14 (36.8) | 1 | 10 | 11 (25) | 1 |
Recurrence | ||||||
Liver | 5 | 4 | 1 | 4 | ||
Lung | 2 | 1 | 1 | 1 | ||
Peritoneum | 1 | 2 | 0 | 2 | ||
Distant lymph node | 2 | 0 | 2 | 0 | ||
Other organ | 1 | 1 | 1 | 1 | ||